Hypoglossal Nerve Stimulation Therapy Market Size, Share & Industry Analysis, By Treatment Devices (Inspire II Upper Airway Stimulation device, Aura 6000 Sleep Therapy System, Others) By Product Type (Implantable, Battery free, Leadless, Electrodes, Others), By Distribution Channel (Hospitals, Specialty Clinics and Diagnostic Laboratories, Research and Academic Institutes) Others and Regional Forecast, 2024-2032

Hypoglossal nerve stimulation also known as pacemaker for the tongue or upper airway stimulation. It is an implantable medical device that electrically stimulates the hypoglossal nerve to the tongue that helps in reduction of obstructive sleep apnea. Additionally, the hypoglossal nerve can be defined as the nerve starting from the brain stem to the neck downwards and again back till tongue. It helps in motor control of tongue muscle as well as voluntary and involuntary functions such as swallowing, and others. Furthermore, hypoglossal nerve stimulator therapy works inside the individual’s body and helps in the natural breathing of the patient’s process by treating sleep apnea. Airways are kept open during sleep helping oxygen to flow naturally. This stimulating device and breathing sensor are implanted in the chest of the patient which are connected to stimulating lead that further connects the hypoglossal nerve. Patients use small handheld remote to operate before going to sleep and once they wake up. Hypoglossal nerve stimulation consists of a programmable pulse-generating system, stimulating electrode, and implantable intrathoracic pressure sensor. In addition to this, hypoglossal nerve stimulation is used for the treatment of obstructive sleep apnea which deals with the most commonly observed sleep disorder indicating continuous start and stops of breathing during sleep.

Rise in prevalence of sleep disorders, rise in geriatric populations, increase in chronic diseases, and others are the major factors that positively driving the growth of the market during the forecast period. Prevalence of obstructive sleep apnea is anticipated to be 2% to 5% of the adult population in Korea, and obstructive sleep apnea is calculated as 4.5% of men and 3.2% of women between 40 to 69 years. Furthermore, FDA approved HGNS therapy in 2014 and is used by over 3,200 patients globally. This therapy was basically for the people diagnosed with moderate to severe obstructive sleep apnea and are unable to get advantages from CPAP (continuous positive airway pressure), not diagnosed with obesity, and others are propelling the growth of the market during the forecast period. Moreover, research and development activities coupled with technological advancement such as miniaturization, automation, and others are positively influencing the growth of the market during the course of the period.

However, the dearth of skilled professionals, stringent regulations, post-operative discomfort, and others are limiting the growth of the market.

Market Segmentation:

Globally, the hypoglossal nerve stimulation therapy market is segmented on bases of treatment devices, product type distribution channel, and region. Based on the treatment devices, the market is segmented Inspire II Upper airway stimulation device, aura 6000 sleep therapy system, and others. Based on the product type the market is classified into implantable, battery free, leadless, electrodes, and others. Based on the end-users, the market is classified into hospitals, specialty clinics and diagnostic laboratories, research and academic institutes, home settings, and others. Geographically, the hypoglossal nerve stimulation therapy market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

The major companies in the Hypoglossal Nerve Stimulation Therapy Market Nyxoah SA., Fisher & Paykel Healthcare Limited, Koninklijke Philips N.V., Curative Medical, Braebon Medical Corporation, BMC Medical Co., Ltd., Oventus, Invacare Corporation, and others.

Key Insights:

• Prevalence of Sleep Disorders Key Countries/ Region, 2018


• Pipeline Analysis, Key Players


• New Product Launches


• Key Industry Developments


• Pricing Analysis

Regional Analysis:

Geographically, hypoglossal nerve stimulation therapy the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is dominating the market owing to the change in lifestyles, rise in obstructive sleep apnea, huge investment in the healthcare industry, and the quick adoption of technology. Europe is the second-largest contributor to the market owing to an increase in health care awareness related to sleep apnea, increased capita income expenditure, increased healthcare infrastructure.

Asia Pacific is anticipated to experience vast growth in the market owing to rise in geriatric population, an increase in healthcare awareness, and an increase in government initiatives towards the healthcare sector, and an increase in the number of research activities. Latin America and Middle East are also anticipated to experience lucrative growth in the market.

Segmentation

Hypoglossal Nerve Stimulation Therapy Industry Developments

• In November 2018, the company Nyxoah SA. launched battery-free and leadless, minimally invasive neurostimulator, ability to deliver bilateral hypoglossal nerve stimulation for moderate to severe OSA patients.